Vident Advisory, LLC Supernus Pharmaceuticals, Inc. Transaction History
Vident Advisory, LLC
- $3.62 Trillion
- Q2 2024
A detailed history of Vident Advisory, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 22,876 shares of SUPN stock, worth $732,032. This represents 0.02% of its overall portfolio holdings.
Number of Shares
22,876
Previous 15,163
50.87%
Holding current value
$732,032
Previous $517 Million
18.31%
% of portfolio
0.02%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding SUPN
# of Institutions
255Shares Held
59.2MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$333 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$196 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$169 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.87MShares$91.7 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$85.8 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.71B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...